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ABSTRACT Previous studies have shown that posttrans-
lational modifications are required for both oncogenic K-ras 4B
protein membrane binding and transforming activity. In ad-
dition, Hancock et al. [Hancock, J. F., Patterson, H. &
Marshall, C. J. (1990) Cell 63, 133-139] found that a polylysine
domain contained at the C terminus of K-ras 4B was also
absolutely essential for K-ras 4B membrane binding but,
surprisingly, neither the polylysine domain nor membrane
binding was required for transforming activity. We have
performed similar studies, but our results are distinctly dif-
ferent. Our studies indicate that the polylysine domain is
crucial for K-ras 4B transforming activity. Moreover, we
demonstrate that although the polylysine domain increases
K-ras 4B membrane binding, significant amounts ofmembrane
binding can occur in the absence of this domain. Finally, while
our studies are consistent with the notion that membrane
binding is required for K-ras 4B transforming activity, we show
that membrane binding, in and of itself, is not sufficient for
efficient K-ras 4B transforming activity.
Ras proteins are critical components of signal transduction
pathways that regulate cell growth and differentiation. Re-
cent studies have shown that extracellular signals (growth
factors, antigens, interleukins, trophic factors, etc.) can
stimulate cell surface receptors to become coupled [via Src
homolog 2/3 (SH2/SH3)-containing adaptor proteins, such
as Grb2] to guanine nucleotide exchange factors (such as
Sos), which can in turn stimulate the conversion of inactive
Ras-GDP to active Ras-GTP (1-3). Ras-GTP can subsequently
interact with the senrne/threonine kinase Raf-1, and following
activation, Raf-1 can initiate a cascade of phosphorylation
[including MAP kinase kinase (MEK), mitogen-activated
protein kinase (MAPK), and pp9O Rsk] that ultimately phos-
phorylates nuclear transcription factors (such as Fos and Jun)
and activates gene expression (1-3).
Human cells contain four distinct but strikingly homolo-
gous Ras proteins (H-ras, N-ras, K-ras 4A, and K-ras 4B)
which primarily differ only in their last 25 aa. [K-ras 4A and
K-ras 4B are encoded by the same gene (KRAS) but contain
alternative fourth exons. In human cells K-ras 4B is- tran-
scribed 10- to 20-fold more than K-ras 4A (4-6).] Although
each of these Ras proteins can be converted into oncogenic
proteins by amino acid substitutions at codon 12, 13, or 61,
oncogenic K-ras proteins are most frequently detected in
human malignancies (4).
Oncogenic Ras proteins are synthesized in the cytosol as
inactive precursors and subsequently undergo a series of
posttranslational modifications which enable them to bind
to the inner surface of cell plasma membranes and trans-
form cells (7-12). These posttranslational modifications are
signaled by the C-terminal 4 aa of Ras proteins and include
isoprenylation, truncation, methylation, and palmitoylation
(8-17). Each of the Ras proteins undergoes isoprenylation,
truncation, and methylation. However, only H-ras, N-ras,
and K-ras 4A proteins undergo palmitoylation (8, 9). Palm-
itoylation, as well as isoprenylation, methylation, and trun-
cation, is important for H-ras, N-ras, and K-ras 4A mem-
brane binding (8). However, membrane binding of non-
palmitoylated K-ras 4B is equivalent to that of H-ras, N-ras,
and K-ras 4A (8, 9, 12). Instead of undergoing palmitoyla-
tion, K-ras 4B (but not H-ras, N-ras, or K-ras 4A) contains
a polylysine domain at its C terminus; and a recent paper
(18) has indicated that this polylysine domain is crucial for
K-ras 4B membrane binding. It has been inferred, there-
fore, that two signals-posttranslational modifications and
a polylysine domain-are required for K-ras 4B membrane
binding. Further, the notion that membrane binding is
essential for Ras transforming activity has been questioned,
because the aforementioned study demonstrated that the
polylysine domain, although essential for K-ras 4B mem-
brane binding, was not required for K-ras 4B transforming
activity. We have performed similar studies,'but our results
are distinctly different. The studies reported herein dem-
onstrate that the polylysine domain is crucial for K-ras 4B
transforming activity and increases, but is not absolutely
essential for, K-ras 4B membrane binding. Moreover, we
show that these effects are mediated through ionic inter-
actions. Finally, although our results are consistent with the
premise that membrane binding is required for K-ras 4B
transforming activity, they indicate that membrane binding,
in and of itself, is not sufficient for complete K-ras 4B
transforming activity.
MATERIALS AND METHODS
Construction of K-ras 4B and GTPase-activating Protein
(GAP)/K-ras 4B Mutants. Oligonucleotide-directed muta-
genesis, PCR mutagenesis, and construction ofDNA vectors
were performed as described (12, 19). For K-ras 4B mutants,
lysine (AAA or AAG codon) was changed to glutamine (CAA
or CAG) or arginine (AGA or AGG). To facilitate distinction
of mutant versus endogenous K-ras 4B by SDS/PAGE,
mutations were introduced into a transforming (Gly12 -* Val)
human K-ras 4B cDNA (6K) that encodes a non-Ras 10-aa
N-terminal leader (20). GAP/6K/CAAX (in the CAAX se-
quence, C is cysteine, A represents an aliphatic residue, and
X can be any of several amino acids) and GAP/6Q/CAAX
hybrids, containing the catalytic domain (aa 705-1047) of
full-length Ras p120 GAP at their N termini and the C-ter-
minal 18 aa of 6K or 6Q at their C termini, were constructed
by using a human GAP cDNA (21). For GAP/6K/SAAX and
GAP/6Q/SAAX, the cysteine (TGT) of 6K or 6Q was
changed to seine (AGT). Tables 1 and 2 summarize the
Abbreviation: GAP, GTPase-activating protein.
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Table 1. Biochemical and biological properties of K-ras 4B proteins
Membrane Methylation,§ Transforming
association,+ Isoprenyl- alkali released/ activity,¶ %
Protein Amino acid sequence* % ationt alkali-stable 3H cpm NIH 3T3 Rat-1
6KI1 RKHKEKMSKDGKKKKKKSKTKVIM 92 + 872/4116 100 100
6R -------RRRRRR- - 89 + 505/1945 108 117
2Q ------.Q-Q- - 83 + 1229/3241 11 <2
4Q -------QQ-Q-Q- - 71 + 775/2911 8 <2
6Q -------QQQQQQ- - 52 + 996/2324 3 <1
SVIM** . ------S--- <5 - 58/2878 0 0
C** ------C <5 - 40/1567 0 0
*The site and nature ofamino acid substitutions are indicated. Hyphens indicate sites where amino acid sequences are identical to 6K sequences.
tRadioactivity in K-ras 4B proteins immunoprecipitated from membrane (cpmm) and cytosol (cpmc) fractions of [35S]methionine/cysteine-
labeled cells was quantitated by liquid scintillation spectroscopy; % membrane association = [cpmm/(cpmm + cpmc)] x 100.
tlsoprenylation of K-ras 4B protein was assessed as outlined in the legend to Fig. 3.
§K-ras 4B proteins immunoprecipitated from [methyl-3H]methionine-labeled cells were treated with 1 M NaOH, and methylation was assessed
by comparing the amount of 3H released from K-ras 4B ([3H]methyl groups are released as [3H]methanol) with the amount of 3H stably
incorporated into K-ras 4B (as [3H]methionine residues).
$NIH 3T3 and Rat-1 cells were transfected with 10 ng and 1 pg, respectively, of K-ras 4B plasmid DNA, and morphologically transformed foci
were quantitated after 14 and 21 days, respectively. Results represent transforming activity relative to the transforming activity of 6K. NIH
3T3 and Rat-1 cells typically develop approximately 3800 and 280 foci, respectively, per Ag of 6K DNA.
IIK-ras 4B protein containing an intact polylysine domain and an activating Val12 mutation.
**Previously described K-ras 4B mutants which are not isoprenylated, methylated, or truncated (12).
specific K-ras 4B and GAP/K-ras 4B mutants, respectively.
Nucleotide sequences of mutants were verified by dideoxy-
nucleotide chain-termination sequencing (22), and mutants
were subsequently cloned into the pZIP-Neo-SV(X)1 retro-
virus expression vector (23).
Cell Transfection and Transformation Assays. For K-ras 4B
constructs, NIH 3T3 cells and Rat-1 cells were transfected,
by calcium phosphate precipitation, with 10 ng and 1 ug,
respectively, of pZIP K-ras 4B plasmid DNA (12). For
GAP/K-ras 4B constructs, NIH 3T3 cells were cotransfected
with 20 ng of pZIP GAP/K-ras 4B plasmid DNA and 1 ,g of
pMUT-1 (pMUT-1 contains a full-length, transforming, ge-
nomic H-ras sequence, containing an activating Gln61 -- Leu
mutation; ref. 24). Cotransfection with transforming H-ras
was necessary, because GAP/K-ras 4B hybrid proteins were
growth inhibitory to nontransformed NIH 3T3 cells. For
focus-forming transformation assays, transfected NIH 3T3
and Rat-1 cells were maintained in Dulbecco's modified
Eagle's medium (DMEM)/10% calf serum and DMEM/
Ham's F10 medium (1:1)/10% calf serum, respectively.
Transformed foci in NIH 3T3 cells and Rat-1 cells were
quantified after 14 and 21 days, respectively (12).
Subcellular Localization of K-ras 4B and GAP/K-ras 4B
Proteins. Subcellularfractionation ofproteins. NIH 3T3 cells
transfected with K-ras 4B or GAP/K-ras 4B were selected
with G418, labeled overnight with [35S]methionine/cysteine
(200 ,uCi/ml; 1 ,uCi = 37 kBq), and separated into crude
membrane and cytosol fractions; K-ras 4B or GAP/K-ras 4B
proteins contained in these fractions were immunoprecipi-
tated with anti-Ras monoclonal antibody Y13-259 (25) or
anti-GAP monoclonal antibody G73 (kindly provided by
Frank McCormick, Onyx Corporation), respectively, and
analyzed by SDS/PAGE and fluorography (12). To quantify
the protein contained in cytosol and membrane fractions,
proteins were eluted from gels, and incorporated radioactiv-
ity was quantified by liquid scintillation spectrometry (26).
Immunofluorescence of K-ras 4B proteins. G418-selected
cells expressing K-ras 4B were grown on glass coverslips,
fixed in 2% formaldehyde, permeabilized in 0.2% saponin,
and incubated successively with primary anti-Ras antibody
(Y13-238), biotinylated goat anti-rat IgG secondary antibody,
and fluorescein-conjugated streptavidin. Immunofluores-
cence was visualized on a confocal fluorescence microscope.
Y13-238 antibody does not efficiently detect endogenous Ras
proteins of NIH 3T3 cells (25).
Detection of Posttranslational Modifications of K-ras 4B and
GAP/K-ras4B Proteins. Detection ofisoprenylation. Isopren-
ylation was assessed by determining whether K-ras 4B or
GAP/K-ras 4B proteins incorporated label derived from
[3H]mevalonic acid (12). G418-selected cells were labeled
overnight with (R,S)-[3H]mevalonolactone (100 ,Ci/ml, in
the presence of 50 ,M compactin; ref. 27), and K-ras 4B
proteins were immunoprecipitated and analyzed by SDS/
PAGE and fluorography.
Detection of methylation. Methylation was assessed by
comparing 3H cpm released with 3H cpm stably retained
following alkali treatment of Ras proteins that had been
metabolically labeled with [methyl-3H]methionine [the radio-
activity from 3H is incorporated into methionine residues and
methyl groups ofproteins (13), but only the methyl groups are
alkali labile]. Briefly, G418-selected cells were labeled over-
night with [methyl-3H]methionine (200 ,uCi/ml; NEN), and
proteins were immunoprecipitated and analyzed by SDS/
PAGE and fluorography (12). Dried gel sections containing
K-ras 4B or GAP/K-ras 4B proteins were cut out and treated
with 1 M NaOH, and radioactivity released from proteins (as
[3H]methanol) or stably retained by proteins (as [3H]methio-
nine) was quantitated by liquid scintillation spectrometry
(13).
Table 2. Biochemical properties of GAP/K-ras 4B hybrid proteins
Membrane Isoprenyl- Methylation, alkali-released/
Protein Amino acid sequence association, % lation alkali-stable 3H cpm
GAP/6K/CAAX* (GAP) SKDGKKKKKKSKTKCVIM 81 + 392/1340
GAP/6Q/CAAX (GAP) ----QQQQQQQ----- 51 + 370/1631
GAP/6K/SAAX (GAP).-.------S 25 34/991
GAP/6Q/SAAX (GAP) ----QQQQQQ----S--- 28 46/1439
*Hybrid protein containing the catalytic domain (aa 705-1047) of full-length Ras p120 GAP at its N terminus and the
C-terminal 18 aa of 6K at its C terminus.
Biochemistry: Jackson et al.
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RESULTS
Membrane Association of K-ras 4B Mutants. To examine
the role of the polylysine domain in K-ras 4B membrane
binding, we transfected NIH 3T3 cells with K-ras 4B con-
structs encoding substitutions of neutral glutamine or basic
arginine for the six contiguous basic lysine residues (Table 1)
and determined the subcellular location of the encoded
mutants. The vast majority of 6K and 6R, containing six
contiguous lysines or arginines, respectively, was associated
with the membrane fraction (92% and 89%, respectively; Fig.
1). In contrast, substitution oftwo (2Q), four (4Q), or six (6Q)
glutamines for the corresponding lysines caused a gradual
(but incomplete) decrease in the amount of Ras protein
associated with the membrane fraction. (The differing mo-
bilities of the K-ras 4B proteins correlate with their differing
net charges.) To demonstrate that the plasma membrane is
the specific membrane component with which K-ras 4B
associates, the subcellular location of K-ras 4B was also
evaluated with confocal immunofluorescence microscopy.
The 6K, 6R, 2Q, and 4Q proteins were predominantly asso-
ciated with the plasma membrane, while substantial amounts
of6Q are associated with the cytoplasm, as well as the plasma
membrane (Fig. 2). These results suggest that although the six
contiguous lysines increase K-ras 4B membrane binding,
substantial amounts of membrane binding can occur in their
absence. Moreover, since membrane association of 6K and
6R are equivalent, these results indicate that the polylysine
domain increases K-ras 4B membrane binding as a result of
its positive charge.
Posttranslational Modifications of K-ras 4B Mutants. Since
posttranslational modifications are crucial for K-ras 4B mem-
brane binding, and 2Q, 4Q, and 6Q have progressively
decreased amounts of membrane binding, we determined
whether these mutants might have comparably decreased
levels of posttranslational modifications. Fig. 3 and Table 1
demonstrate that 6K, 6R, 2Q, 4Q, and 6Q are all efficiently
isoprenylated and methylated. (The amount of labeling with
[3H]mevalonolactone relative to the amount of labeling with
[35S]methionine/cysteine was comparable for all the K-ras
4B proteins; data not shown.) These results demonstrate that
the polylysine domain is not required for CAAX-signaled
posttranslational modifications to occur and suggest that the
polylysine domain directly increases K-ras 4B membrane
binding. These results also indicate that posttranslational
modifications, although absolutely required, are not in them-
selves completely sufficient for full K-ras 4B membrane
binding.
FIG. 2. Immunofluorescence of K-ras 4B proteins in cells ex-
pressing 6K (A), 6R (B), 2Q (C), 4Q (D), or 6Q (E). Control NIH 3T3
cells (F) contained no exogenous K-ras 4B. G418-selected NIH 3T3
cells were fixed in formaldehyde and permeabilized with saponin,
and K-ras 4B proteins contained in these cells were stained with
fluorescein. Immunofluorescence was visualized on a confocal flu-
orescence microscope.
Effect of the Polylysine Domain and CAAX Motif on Sub-
cellular Location of a Heterologous, Cytoplasmic GAP. To
further assess the relative contributions of the polylysine
domain and/or posttranslational modifications to K-ras 4B
membrane binding, we determined whether the addition of a
polylysine domain and/or posttranslational modifications to
the C terminus of the catalytic domain of Ras p120 GAP (a
cytoplasmic protein which stimulates Ras GTPase activity;
ref. 21) could convert the predominantly cytoplasmic cata-
lytic GAP protein into a membrane-bound protein. Table 2
summarizes the specific GAP/K-ras 4B hybrid proteins gen-
erated. GAP/6K/CAAX, containing six contiguous lysines,
was predominately membrane-associated, whereas GAP/
6Q/CAAX containing six glutamines substituted for the
lysines, was only -50% membrane associated'(Fig. 4). (Both
GAP/6K/CAAX and GAP/6Q/CAAX are isoprenylated and
methylated; Table 2 and data not shown.) Moreover, when
isoprenylation, methylation, and truncation were prevented
(GAP/6K/SAAX and GAP/6Q/SAAX), only -25% of the
hybrid proteins were membrane associated. (Catalytic GAP,
containing no K-ras 4B sequences, was also =25% membrane
associated; data not shown.) Our results with these GAP/
K-ras 4B hybrids parallel our results with full-length K-ras 4B
proteins. Although the polylysine domain (in conjunction
with posttranslational modifications) increases membrane
binding of catalytic GAP, substantial amounts of membrane
binding occur with posttranslational modifications alone, in
the absence of the polylysine domain. Our results also
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FIG. 1. Subcellular fractionation of K-ras 4B proteins. G418-
selected NIH 3T3 cells were labeled with [35S]methionine/cysteine
and separated into crude membrane (pellet, P) and cytosol (super-
natant, S) fractions, and K-ras 4B proteins contained in these
fractions were immunoprecipitated and analyzed by SDS/PAGE and
fluorography. NIH, untransfected NIH 3T3 cells; arrowheads, po-
sitions of mutant K-ras 4B proteins containing a 10-aa N-terminal
leader; solid arrow, position of endogenous Ras proteins. The
differing mobilities of K-ras 4B proteins correlate with their differing
net charges.
6K 6R 2Q 4Q 6Q NIH
FIG. 3. Isoprenylation of K-ras 4B proteins. G418-selected NIH
3T3 cells were labeled with [3H]mevalonolactone, and K-ras 4B
proteins contained in these cells were immunoprecipitated and
analyzed by SDS/PAGE. Arrowheads, mutant K-ras 4B proteins;
solid arrow, endogenous Ras proteins.
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suggest that the C-terminal 18 aa of K-ras 4B (in conjunction
with posttranslational modifications) may be sufficient for
K-ras 4B membrane binding.
Transformation Efficiency of K-ras 4B Mutants. Given the
role of the polylysine domain in K-ras 4B membrane binding,
we determined its role in K-ras 4B transforming activity. As
shown in Table 1, 6K and 6R are highly and equally trans-
forming. In contrast, 2Q, 4Q, and 6Q all have drastically
reduced transforming activity. Moreover, there is little cor-
relation between the amount of m'embrane association and
the transforming activity of mutant K-ras 4B proteins. For
instance, in NIH 3T3 cells, the transforming activity of 2Q is
decreased 90%, but its membrane association is decreased
only 10%, relative to 6K. Similarly, 4Q and 6Q have 92% and
97%, respectively, decreases in transforming activity but
only 23% and 44%, respectively, decreases in membrane
association. These results suggest that a completely intact
polylysine domain may be required for optimal K-ras 4B
transforming activity. In addition, these results demonstrate
that membrane binding, in and of itself, is not sufficient for
efficient K-ras 4B transforming activity.
DISCUSSION
Our results indicate that the polylysine domain is crucial for
K-ras 4B transforming activity. Indeed, the almost equivalent
decrease in transforming activity of K-ras 4B mutants con-
taining two, four, or six Lys -* Gln substitutions (2Q, 4Q, and
6Q) suggests that all six lysines of the polylysine domain may
be required for efficient transforming activity. In addition,
although the polylysine domain significantly increases K-ras
4B membrane binding, -50% of K-ras 4B remains membrane
bound in the absence of this domain. Finally, our studies (and
the studies of Hancock et al.; ref. 28), which demonstrate that
positively charged arginine residues can very efficiently
substitute for the six lysines of K-ras 4B, suggest that the
polylysine domain likely facilitates membrane binding and
enables cell transformation via ionic interactions with a
negatively charged domain of a target protein and/or nega-
tively charged membrane phospholipid headgroups.
The abrupt and dramatic decrease in transforming activity
of 2Q, 4Q, and 6Q K-ras 4B mutants-despite their gradual
and modest decrease in membrane association-suggests
that membrane binding, in and of itself, is not sufficient for
efficient K-ras 4B cell transformation. Binding to a specific
membrane target site (and/or lipid environment) may be
equally or more important than the absolute amount of
membrane binding. Specific membrane binding can occur
through a variety of noncovalent bonds. Therefore, the
polylysine domain (through its ability to form ionic bonds)
and posttranslational modifications (through their ability to
facilitate hydrophobic and van der Waals interactions) could
create a binding domain in K-ras 4B that specifically interacts


















FIG. 4. Subcellular fractionation of GAP/K-ras 4B proteins.
G418-selected NIH 3T3 cells were labeled with [35S]methionine/
cysteine and separated into crude membrane (pellet, P) and cytosol
(supernatant, S) fractions, and GAP/K-ras 4B proteins contained in
these fractions were immunoprecipitated and analyzed by SDS/
PAGE and fluorography.
-) Gln substitutions may not significantly decrease absolute
membrane binding, these substitutions could structurally
alter the K-ras 4B binding domain and thereby prevent
specific membrane binding, signal transduction, and cell
transformation. [Since previous studies have shown that an
N-terminal myristate (29, 30) or a C-terminal geranylgeranyl
group (28, 31) can efficiently substitute for the farnesyl group
of oncogenic, but not normal, Ras proteins, a nonspecific
lipid membrane anchor, in conjunction with a polylysine
domain, may be sufficient for oncogenic, but not normal, Ras
proteins.] Alternatively, the polylysine domain may facilitate
the binding of K-ras 4B to a critical nonmembrane target. At
any rate, whether or not the polylysine domain (alone or in
conjunction with posttranslational modifications) enables
K-ras 4B to bind a membrane and/or nonmembrane tar-
get(s)-if this binding is required for transforming activity-
mutations which prevent this binding will prevent transform-
ing activity.
As noted above, =50% of K-ras 4B remains membrane
associated in the absence of a polylysine domain. Posttrans-
lational modifications could account for this residual mem-
brane association. Alternatively, since 16 ofthe C-terminal 25
aa of K-ras 4B are charged (see Table 1), some or all of these
additional charged residues could also account for the resid-
ual membrane association.
Our results clearly indicate that posttranslational modifi-
cations, in the absence of a polylysine domain, are not
sufficient for complete membrane binding or efficient trans-
forming activity. Likewise, previous studies have shown that
the polylysine domain, in the absence of posttranslational
modifications, is also not sufficient for membrane binding or
transforming activity (see Table 1, SVIM and C mutants; refs.
8, 12, 32, and 33). However, the polylysine domain, in
conjunction with posttranslational modifications, is sufficient
to promote membrane binding of the cytosolic catalytic
domain of Ras p120 GAP as well as cytosolic protein A (28),
and this membrane-bound catalytic GAP (but not cytosolic
catalytic GAP) can inhibit the transforming activity of onco-
genic H-ras (ref. 34 and unpublished results). Polylysine
domains and posttranslational modifications could, there-
fore, represent a general cellular mechanism to facilitate the
membrane binding and biologic activity of a variety of
different proteins.
We do not know whether there are significant biologic
differences between K-ras 4B, which contains a polylysine
domain, and H-ras, N-ras, and K-ras 4A proteins, which are
palmitoylated. However, other Ras superfamily proteins
(such as Rap and Rho) also have palmitoylated and nonpalm-
itoylated counterparts; and the nonpalmitoylated counter-
parts often contain polybasic domains (35-37). Since the
polylysine domain should form ionic bonds, whereas palmi-
tate should facilitate hydrophobic and van der Waals inter-
actions, the polylysine domain and palmitate modification(s)
may direct K-ras 4B and H-ras, N-ras, or K-ras 4A proteins,
respectively, to different targets. Furthermore, since palmi-
toylation is transient (tv½ < 20 min; ref. 36), there could be
significant differences in the way proteins containing perma-
nent polybasic domains versus transient palmitate modifica-
tions are regulated.
The studies presented here were performed concurrently
with those of Hancock et al. (18, 28). However, there are
several distinct differences between our results. They ob-
served a 220-fold decrease in membrane association but
found only an =2-fold reduction in transforming activity
when glutamines were substituted for the six contiguous
lysines of [Val121K-ras 4B. In contrast, we found a <2-fold
reduction in membrane association and a 30-fold decrease in
transforming activity with our similarly substituted [Val12]K-
ras 4B mutant. The implications of our studies are quite
different from those of the studies by Hancock et al. Their
Biochemistry: Jackson et al.
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results suggest that (i) two signals-posttranslational modi-
fications and a polylysine domain-are absolutely essential
for K-ras 4B membrane binding and (ii) neither the polylysine
domain nor membrane binding is required for K-ras 4B
transformation. In contrast, our results indicate that the
polylysine domain is crucial for transformation and demon-
strate that significant amounts of membrane binding can
occur in the absence of the polylysine domain. While our
studies are consistent with the notion that membrane binding
is required for K-ras 4B transforming activity, our results
clearly indicate that membrane binding, in and of itself, is not
sufficient for efficient transforming activity. The difference in
transforming activity observed by us and by Hancock et al.
is most likely explained by the different susceptibilities ofour
two clones of NIH 3T3 cells to transformation, because we
do not detect a significant difference in transforming activity
between their or our Gln6-substituted mutant when we trans-
fect these constructs into our NIH 3T3 or Rat-1 cells (<1%
and 3%, or <1% and <1%, transforming activity, respec-
tively, relative to [ValI2]K-ras 4B). In regard to the observed
differences in membrane association, we utilized NIH 3T3
cells both to quantitate transforming activity and to perform
subcellular fractionations, whereas Hancock et al. utilized
NIH 3T3 cells to quantitate transforming activity but per-
formed subcellular fractionations on COS cells. When we
performed subcellular fractionations on NIH 3T3 cells trans-
fected with either their or our Gln6-substituted K-ras 4B
mutant, we found that the levels of membrane association of
these two proteins were not significantly different (45% and
51% membrane associated, respectively).
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